June 24, 2020
Sara Hurvitz, MD, medical oncologist, Ronald Reagan UCLA Medical Center, and Sherene Loi, PhD, senior medical oncologist, Peter MacCallum Cancer Center, discuss their recent study, HER2CLIMB, highlighting the positive findings that include the reduction of intracranial progression and death among patients with breast cancer treated with tucatinib.
Lin NU, Murthy RK, Anders CK, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). J Clin Oncol. 38: 2020 (suppl; abstr 1005). doi: 10.1200/JCO.2020.38.15_suppl.1005